---
title: "Psych News Alert: FDA Warns of Rare but Serious Skin Reaction Reportedly Linked to Olanzapine"
description: The FDA on Tuesday issued a warning  that the antipsychotic olanzapine may cause a rare but serious skin reaction that can progress to ot...
image: https://alert.psychnews.org/hubfs/Imported_Blog_Media/fda_2014_fw-Jun-24-2025-10-25-38-6695-PM.png
---

 5/11/16 12:00 AM

# FDA Warns of Rare but Serious Skin Reaction Reportedly Linked to Olanzapine

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [ Psychiatric News Alert ](https://alert.psychnews.org/author/psychiatric-news-alert)

Share: [facebook-f icon ](http://www.facebook.com/share.php?u=https://alert.psychnews.org/2016/05/fda-warns-of-rare-but-serious-skin.html) [linkedin-in icon ](http://www.linkedin.com/shareArticle?mini=true&url=https://alert.psychnews.org/2016/05/fda-warns-of-rare-but-serious-skin.html) [Twitter icon ](https://twitter.com/intent/tweet?url=https://alert.psychnews.org/2016/05/fda-warns-of-rare-but-serious-skin.html) [pinterest-p icon ](http://pinterest.com/pin/create/link/?url=https://alert.psychnews.org/2016/05/fda-warns-of-rare-but-serious-skin.html) [envelope icon ](mailto:?body=https://alert.psychnews.org/2016/05/fda-warns-of-rare-but-serious-skin.html)

| ![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/fda_2014_fw-Jun-24-2025-10-25-37-6321-PM.png?width=200&height=84&name=fda_2014_fw-Jun-24-2025-10-25-37-6321-PM.png) |  |
| --- | --- |

The FDA on Tuesday issued a [warning](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm500123.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery) that the antipsychotic olanzapine may cause a rare but serious skin reaction that can progress to other parts of the body. According to the announcement, a warning about this severe condition—known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)—will now appear on all olanzapine-containing products.

According to the [FDA Adverse Event Reporting System](http://www.fda.gov/Safety/MedWatch/default.htm) database, 23 worldwide cases of olanzapine-related DRESS have been identified since the drug’s approval in 1996.

DRESS causes an abnormally high number of eosinophils (infection-fighting white blood cells), which can lead to inflammation or swelling. DRESS commonly starts as a rash but can also be accompanied by a fever, swollen lymph nodes, and a swollen face. The swelling and inflammation can spread to internal organs, causing organ damage, and can lead to death. While there is no specific treatment for DRESS, the FDA recommends the syndrome is best managed by early recognition, discontinuation of the offending medication, and supportive care.

The FDA advises health care professionals prescribing olanzapine to make patients aware of the risks associated with the medication and stop treating patients with olanzapine if DRESS is suspected. Any side effects involving olanzapine should be reported to the [FDA MedWatch program](https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home).

For related information, see the *Psychiatric News* article “[Antipsychotics May Contribute to Cases of Acute Pancreatitis](http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2016.PP3b1).”

[FDA warning](https://alert.psychnews.org/tag/fda-warning), [olanzapine](https://alert.psychnews.org/tag/olanzapine), [antipsychotics](https://alert.psychnews.org/tag/antipsychotics), [skin reaction](https://alert.psychnews.org/tag/skin-reaction), [DRESS](https://alert.psychnews.org/tag/dress), [Food and Drug Administration](https://alert.psychnews.org/tag/food-and-drug-administration)

## Related posts

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/hands_hospital_iStock-175226565-Jun-24-2025-07-22-33-3345-PM.jpg?height=200&name=hands_hospital_iStock-175226565-Jun-24-2025-07-22-33-3345-PM.jpg) ](https://alert.psychnews.org/2019/09/risks-of-antipsychotics-for-treatment.html)

[olanzapine](https://alert.psychnews.org/tag/olanzapine), [risperidone](https://alert.psychnews.org/tag/risperidone), [quetiapine](https://alert.psychnews.org/tag/quetiapine), [hospital length of stay](https://alert.psychnews.org/tag/hospital-length-of-stay), [antipsychotics](https://alert.psychnews.org/tag/antipsychotics), [delirium](https://alert.psychnews.org/tag/delirium), [mortality](https://alert.psychnews.org/tag/mortality), [hospitalized patients](https://alert.psychnews.org/tag/hospitalized-patients), [haloperidol](https://alert.psychnews.org/tag/haloperidol)

## [Risks of Antipsychotics for Treatment of Delirium May Outweigh Benefits, Review Finds](https://alert.psychnews.org/2019/09/risks-of-antipsychotics-for-treatment.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 9/6/19 12:00 AM

There may be no benefits to treating hospitalized patients experiencing delirium with...

[ Read more ](https://alert.psychnews.org/2019/09/risks-of-antipsychotics-for-treatment.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/prescription_iStock-1471076001.jpg?height=200&name=prescription_iStock-1471076001.jpg) ](https://alert.psychnews.org/are-antipsychotics-equally-effective-for-acute-schizophrenia)

[schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [olanzapine](https://alert.psychnews.org/tag/olanzapine), [risperidone](https://alert.psychnews.org/tag/risperidone), [antipsychotic](https://alert.psychnews.org/tag/antipsychotic), [weight gain](https://alert.psychnews.org/tag/weight-gain), [prolactin](https://alert.psychnews.org/tag/prolactin), [sedation](https://alert.psychnews.org/tag/sedation)

## [Are Antipsychotics Equally Effective for Acute Schizophrenia?](https://alert.psychnews.org/are-antipsychotics-equally-effective-for-acute-schizophrenia)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 10/29/25 2:04 PM

Among seven commonly prescribed antipsychotics, olanzapine and risperidone might be the most...

[ Read more ](https://alert.psychnews.org/are-antipsychotics-equally-effective-for-acute-schizophrenia)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/pharmacist_iStock-1010456164-Jun-24-2025-06-24-25-5109-PM.jpg?height=200&name=pharmacist_iStock-1010456164-Jun-24-2025-06-24-25-5109-PM.jpg) ](https://alert.psychnews.org/2021/02/switching-to-aripiprazole-or.html)

[aripiprazole](https://alert.psychnews.org/tag/aripiprazole), [meta-analysis](https://alert.psychnews.org/tag/meta-analysis), [Schizophrenia Bulletin](https://alert.psychnews.org/tag/schizophrenia-bulletin), [cholesterol](https://alert.psychnews.org/tag/cholesterol), [treatment adherence](https://alert.psychnews.org/tag/treatment-adherence), [antipsychotics](https://alert.psychnews.org/tag/antipsychotics), [weight gain](https://alert.psychnews.org/tag/weight-gain), [ziprasidone](https://alert.psychnews.org/tag/ziprasidone)

## [Switching to Aripiprazole or Ziprasidone May Reduce Weight Gain in Patients Taking Antipsychotics](https://alert.psychnews.org/2021/02/switching-to-aripiprazole-or.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 2/16/21 12:00 AM

[ Read more ](https://alert.psychnews.org/2021/02/switching-to-aripiprazole-or.html)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Psychiatric News Alert",
    "url" : "https://alert.psychnews.org/author/psychiatric-news-alert"
  },
  "dateModified" : "2025-06-24T22:28:25.890Z",
  "datePublished" : "2016-05-11T04:00:00.000Z",
  "headline" : "Psych News Alert: FDA Warns of Rare but Serious Skin Reaction Reportedly Linked to Olanzapine",
  "image" : [ "https://alert.psychnews.org/hubfs/Imported_Blog_Media/fda_2014_fw-Jun-24-2025-10-25-38-6695-PM.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://alert.psychnews.org/2016/05/fda-warns-of-rare-but-serious-skin.html",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://alert.psychnews.org/hubfs/PN-Blue-Box.jpg"
    }
  }
}
```